( : relative;> Neurochem continues to ...)At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed),Health

Neurochem continues to expect to announce the top-line results of the trial during the second quarter of this year, although they may not be available within this timeframe. The actual timing of the release of these top-line results depends on completing the adjustments to the initial statistical model.

Alzheimer's Association News Briefing

The Alzheimer's Association has invited Dr. Aisen to present on the tramiprosate (ALZHEMED(TM)) program for inclusion in a news briefing to be held today, June 11, 2007, at 12:00 P.M. (ET).

Continuing Medical Education Symposium

Neurochem is also supporting a CME symposium on June 11 at 6:30 PM at the conference. The symposium, entitled Confronting the Burgeoning AD Crisis: New Frontiers, is sponsored by Professional Postgraduate Services(R). The invited faculty presenters are Howard M. Fillit, MD, Steven T. DeKosky, MD and Serge Gauthier, MD, and they will examine the burden of AD and assess the need for improving diagnosis, with a special focus on shifting the treatment paradigm from managing symptoms to treating the underlying causes of the disease.

Neurochem Poster Presentations

Neurochem is also exhibiting three poster presentations on tramiprosate (ALZHEMED(TM)) at this conference. All posters are displayed in the Exhibit Hall of the Marriott Wardman Park Hotel, open on June 10 from 10:30 A.M. to 6:30 P.M. (ET) and on June 11 from 9:30 A.M. to 4:30 P.M. (ET).

    - Presentation P-187, entitled Tramiprosate Is Neuroprotective and

      Reduces the Levels of Secreted Amyloid-ss in Organotypic Hippocampal

      Slice Cultures, will be presented by lead author Mounia Azzi.

    - Andre Galarneau will present GABA-Dependent Pathways in the

      Neuroprotective Effect of Tramiprosate against Amyloid-ss Toxicity

      in presentation P-190.

    - Barry D. Greenberg will present Tramiprosate Decreases Amyloid-ss

      Induced Erk1/2 Activity in Primar
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able
to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation
in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in
Alzheimers Disease at International Conference on Prevention of
Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease
Modification Trial Designs at Alzheimers ConferenceCurrent
Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease
Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on
All Five Efficacy Endpoints in Alzheimers Disease Trial After One
Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month
Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From
Dimebon Phase 2 Alzheimers Disease Trial at American Academy of
Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the
Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro
Studies for Promising Alzheimers Drug